Brittany 地区囊性纤维化出生发病率 50 年变化趋势研究
Temporal and spatial trends in cystic fibrosis birth incidence over 50 years in Brittany, France
从 1975 年到 2024 年,法国布列塔尼地区囊性纤维化(CF)的出生发病率下降了 50.1%(从 1/2,175 降至 1/4,361,p < 0.001)。研究发现,西部布列塔尼的发病率比东部高 84.9%(p = 0.035)。尽管囊性纤维化治疗有所进步,但地区间差异仍在扩大。
- Julie Derrien1,
- Carine L’Hostis1,
- Marie-Pierre Audrézet1,2,
- Sophie Ramel1,3,
- Chantal Belleguic4,
- Eric Deneuville5,
- Baptiste Arnouat6,
- Claude Férec1 &
- …
- Virginie Scotet1
We’re sharing this article early to provide faster access to peer-reviewed, accepted research. It is citable and carries a permanent DOI. This version is subject to further edits and will be replaced automatically by the final Version of Record. All legal disclaimers apply.
Abstract
The clinical landscape of cystic fibrosis (CF), one of the most common rare genetic diseases, has evolved considerably over time due to major advances in disease care and management, the widespread implementation of newborn screening (NBS) and the recent emergence of highly effective CFTR modulator therapies. In Brittany (western France), where CF is particularly common, the establishment of a registry tracking all people with CF (pwCF) born since the 1970s, as well as the early implementation of NBS for CF in 1989, offers the opportunity to accurately monitor long-term trends in birth incidence. This study aimed to examine temporal and spatial trends in CF birth incidence in Brittany over 50 years. This study focused on pwCF born in Brittany between 1975 and 2024 (n = 599). Patients born before 1989 were recorded by combining data sources, whereas others were identified from the NBS programme for CF. Temporal and spatial trends in incidence rates were modelled using Poisson regression and summarised as the average percent change between periods or departments. In Brittany, the birth incidence of CF decreased significantly by 50.1% between the 1975-84 and 2015-24 decades (1/2,175 vs. 1/4,361, p < 0.001), with a clear breakpoint observed from the 1990s. The west-to-east gradient previously observed in Brittany appears to have strengthened over the study period. During the last decade (2015-24), western Brittany exhibited a birth incidence rate 84.9% higher than that of eastern Brittany (1/3,120 vs. 1/5,769, p = 0.035). No upward trend has yet been observed since the expansion of access to elexacaftor/tezacaftor/ivacaftor (ETI) therapy in France. This study reports a significant decline in the birth incidence of CF in Brittany over the past 50 years, with a clear breakpoint coinciding with the availability of prenatal diagnosis. The analyses also highlight the strengthening of spatial disparities, with a higher incidence in western Brittany, a peninsula with lower population mixing. Ongoing monitoring remains essential to assess the potential effect of the recent advent of CFTR modulator therapies.
Abbreviations
- APC:
-
Average percent change
- CF:
-
Cystic fibrosis
- CFTR:
-
Cystic fibrosis transmembrane conductance regulator
- CRMS/CFSPID:
-
Cystic fibrosis transmembrane conductance regulator-related metabolic syndrome/cystic fibrosis screen positive, inconclusive diagnosis
- ETI:
-
Elexacaftor/tezacaftor/ivacaftor
- IRT:
-
Immunoreactive trypsinogen
- NBS:
-
Newborn screening
- pwCF:
-
People with cystic fibrosis
- 95% CI:
-
95% confidence interval
Acknowledgements
We thank all the physicians involved in the care of CF patients in Brittany and in the neighbouring Loire-Atlantique department for their contribution to the creation of the regional registry. We also thank the Regional Newborn Screening Centre in Rennes for providing aggregated screening data. This work was supported by the Association de Transfusion Sanguine et de Biogénétique Gaëtan Saleün and the Association La Pierre Le Bigaut Mucoviscidose.
Funding
This work was supported by a grant from the French Cystic Fibrosis Association “Vaincre La Mucoviscidose” [RC20200502649]. This sponsor has no role in the study, nor in the writing or the submission of the article.
Author information
Authors and Affiliations
Univ Brest, Inserm, EFS, UMR 1078, GGB, Brest, France
Julie Derrien, Carine L’Hostis, Marie-Pierre Audrézet, Sophie Ramel, Claude Férec & Virginie Scotet
Laboratory of Molecular Genetics, University Hospital, Brest, France
Marie-Pierre Audrézet
CF Centre, Ildys Foundation, Roscoff, France
Sophie Ramel
CF Centre, University Hospital, Rennes, France
Chantal Belleguic
CF Centre, South Hospital, Rennes, France
Eric Deneuville
CF Centre, Chubert Hospital, Vannes, France
Baptiste Arnouat
Authors
- Julie Derrien
- Carine L’Hostis
- Marie-Pierre Audrézet
- Sophie Ramel
- Chantal Belleguic
- Eric Deneuville
- Baptiste Arnouat
- Claude Férec
- Virginie Scotet
Corresponding authors
Correspondence to Julie Derrien or Virginie Scotet.
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethics approval and consent to participate
This research protocol was approved by the ethical committee of the University Hospital of Brest, and the French data protection authority (Commission Nationale de l’Informatique et des Libertés). As there was no direct interaction/participation with human participants during the research process, individual informed consent was not required for the scope of this study.
Consent for publication
Not applicable.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Derrien, J., L’Hostis, C., Audrézet, MP. et al. Temporal and spatial trends in cystic fibrosis birth incidence over 50 years in Brittany, France. Sci Rep (2026). https://doi.org/10.1038/s41598-026-80268-9
Received: 25 June 2026
Accepted: 05 November 2026
Published: 14 November 2026
DOI: https://doi.org/10.1038/s41598-026-80268-9
Keywords
来源:Nature 健康护理主题 · nature.com